SMS Pharmaceuticals Limited said that it has secured certificate of suitability (CEP) approval from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for Ibuprofen.

The approval will allow the Indian pharmaceutical company to launch sales of Ibuprofen in the European markets.

P. Vamsi Krishna — SMS Pharmaceuticals Executive Director said: “We are pleased to receive the CEP approval for Ibuprofen by the EDQM. This we believe is a testimony of the company’s quality standards and capabilities.

“The company will continue to explore avenues to further grow the revenue from Ibuprofen. The company’s growth trajectory is expected to accelerate further, in the upcoming quarters underpinned by the recovery in the key products and further geographic expansion for Ibuprofen and other products.”

  EDQM, Ibuprofen, India, P. Vamsi Krishna, SMS Pharmaceuticals